Abstract
The bioavailability of the new antischistosomal agent, oltipraz, was examined under three different dietary conditions in seven healthy males. Oltipraz tablets (500 mg) were administered in single doses (25 mg/kg) under fasting conditions, with a low fat meal (less than 5% fat) and a high fat meal (24% fat). The extent and rate of oltipraz bioavailability were significantly increased by concurrent administration of the drug with food, as demonstrated by the increase in the plasma peak concentration, the area under the plasma concentration vs. time curve and the absorption rate constant. The plasma peak concentration was also reached earlier. Oltipraz plasma concentrations, following its administration under fasting conditions, were almost negligible. The likely mechanisms underlining oltipraz-food interaction are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
